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There is increased incidence of microsatellite instability (MSI) in patients who develop multiple primary colorectal cancers (CRC),
although the association with hereditary nonpolyposis colon cancer (HNPCC) is unclear. This study aims to evaluate the underlying
genetic cause of MSI in these patients. Microsatellite instability was investigated in 111 paraffin-embedded CRCs obtained from 78
patients with metachronous and synchronous cancers, and a control group consisting of 74 cancers from patients with a single CRC.
Tumours were classified as high level (MSI-H), low level (MSI-L) or stable (MSS). MLH1, MSH2 and MSH6 gene expression was
measured by immunohistochemistry. Methylation of the MLH1 promoter region was evaluated in MSI-H cancers that failed to
express MLH1, and mutational analysis performed in MSI-H samples that expressed MLH1, MSH2 and MSH6 proteins. The frequency
of MSI-H was significantly greater in the multiple, 58 out of 111 (52%), compared to the single cancers, 10 out of 74 (13.5%), Po0.01.
Of the 32 patients from whom two or more cancers were analysed, eight (25%) demonstrated MSI-H in both cancers, 13 (41%)
demonstrated MSI-H in one cancer and 11 (34%) failed to demonstrate any MSI-H. MSI-H single cancers failed to express MLH1 or
MSH2 in seven out of nine (78%) cases and MSI-L/MSS cancers failed to express MLH1 or MSH2 in one out of 45 (2.2%) cases, all
cancers expressed MSH6. MSI-H multiple cancers failed to express MLH1 or MSH2 in 21 out of 43 (48%) cases and MSI-L/MSS
cancers failed to express MLH1 or MSH2 in four out of 32 (12.5%) cases. MSH6 expression was lost in five MSI-H multiple cancers,
four of which also failed to express MLH1 or MSH2. Loss of expression of the same mismatch repair (MMR) gene was identified in
both cancers from six out of 19 (31%) patients. Methylation was identified in 11 out of 17 (65%) multiple and three out of six (50%)
single MSI-H cancers that failed to express MLH1. Mutational analysis of 10 MSI-H multiple cancers that expressed MLH1, MSH2 and
MSH6 failed to demonstrate mutations in the MLH1 or MSH2 genes. We suggest that, although MSI-H is more commonly identified
in those with multiple colorectal cancers, this does not commonly arise from a classical HNPCC pathway.
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Colorectal cancer (CRC) develops via two distinct genetic path-
ways. The ‘suppressor’ pathway involves loss of function of the
tumour suppressor genes APC, DCC and p53, and the activation
of the proto-oncogene k-ras. This accounts for 85% of sporadic
CRC (Ilyas et al, 1999) and for cancers associated with familial
adenomatous polyposis (FAP), that constitute 1% of all CRC
(Vasen, 2000). In the ‘mutator’ pathway, mutations in mismatch
repair (MMR) genes such as MLH1, MSH2, MSH6, PMS1 and PMS2
lead to microsatellite instability (MSI) in genes such as TGFbRII,
ILGF, E2F-4 and BAX, whose coding regions are closely associated
with microsatellite DNA (Markowitz et al, 1995; Souza et al, 1996,
1997; Rampino et al, 1997). Microsatellite instability is detected
in 15% of sporadic CRC and 90% of cancers from patients with
hereditary nonpolyposis colon cancer (HNPCC), which accounts
for 1–2% of all CRC (Aaltonen et al, 1998; Percesepe et al, 2001;
Samowitz et al, 2001).
Microsatellite instability is classified according to the level of
instability detected as high (MSI-H), low (MSI-L) or stable (MSS)
(Boland et al, 1998). In MSI-H sporadic cancers, there is
predominantly loss of MLH1 function (Thibodeau et al, 1998),
caused by transcriptional silencing of the gene brought about by
methylation of the MLH1 promoter region (Herman et al, 1998).
Hereditary nonpolyposis colon cancer associated cancers arise
from MLH1 and MSH2 germline mutations and rarely involve
mutations of other genes (Liu et al, 1996; Peltomaki and Vasen,
1997) or MLH1 promoter region methylation (Wheeler et al, 2000;
Potocnik et al, 2001; Yamamoto et al, 2002).
At least half the patients with HNPCC will develop a
metchronous CRC when treated by a standard colorectal resection
(Lynch, 1996), and the Bethesda criteria, introduced to identify
those with HNPCC advise MSI analysis in patients with multiple
CRC (Rodriguez-Bigas et al, 1997). Microsatellite instability has
been reported in 33–89% of cancers from patients with multiple
cancers (Horii et al, 1994; Sengupta et al, 1997), including studies
that excluded HNPCC clinically by the Amsterdam criteria (Brown
et al, 1998; Masubuchi et al, 1999; Yamashita et al, 2000), although
these results have been disputed (Pedroni et al, 1999). The
Amsterdam criteria were not sufficiently selective (Beck et al,
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s1997), since the more rigorous Amsterdam criteria II (Vasen et al,
1999) and atypical HNPCC phenotypes associated with mutations
in other MMR genes such as MSH6 (Wagner et al, 2001) were not
considered. The underlying genetic cause in patients who develop
metachronous or synchronous cancers is not clear, germline
mutations in MLH1 and MSH2 account for 90% of cases of
HNPCC, with mutations in MSH6 and PMS2 accounting for the
remainder (Giardiello et al, 2001).
This study investigates the incidence of MSI in patients from
the general population with multiple primary colorectal cancers,
and the relevance of MLH1, MSH2 and MSH6 gene expression in
identifying those patients who may have HNPCC.
MATERIALS AND METHODS
Patients
From the Thames cancer registry, 754 patients who developed
either synchronous (393) or metachronous (361) colorectal cancers
between 1972 and 1997 were identified, 387 females and 367 males,
with a median age at diagnosis of 70 (range 32–94) years. There
were 986 cancers in the left colon and 694 cancers in the right
colon. The pathology departments of all hospitals identified by
the registry were contacted, 12 of these agreed to supply tissue for
this study and provided us with 111 samples of paraffin-embedded
cancer tissue and corresponding normal mucosa from 78 patients
(44 females, 34 males, median age 72 (range 35–91) years). A
cancer was synchronous when detected within 2 years of the first
(index) cancer, and metachronous when it occurred later. There
were 52 synchronous cancers from 29 patients and 59 metachro-
nous cancers from 49 patients, with two or more cancers from 32
patients available for analysis. There were 56 cancers in the left
colon and 51 in the right side of the colon; the site of origin of
four cancers was undetermined. A control group of 74 patients (31
females, 43 males, median age 74, range 38–100 years) with single
CRC resected at least 7 years earlier was identified. There were 42
cancers in the left colon and 29 in the right colon; the site of origin
of three cancers was undetermined. Paraffin-embedded cancer
tissue and the corresponding normal mucosa were obtained from
the resected specimens. Regional ethics committee approval for
this study was obtained on the condition that all data were
anonymous and that contact with patients to obtain family history
was strictly prohibited.
Analysis of MSI
DNA was extracted from the paraffin-embedded tissue using a
standard technique (Sengupta et al, 1997) and microsatellite
DNA was amplified by polymerase chain reaction (PCR) at the
mononucleotide loci Bat 26, Bat 25 and Bat 40, and the
dinucleotide loci D2S123, D5S346 and D17S250. Each PCR reaction
mixture consisted of: 20-deoxynucleoside 50-triphosphates
0.2mmoll
 1 (Pharmacia, St Albans, UK); 1 PCR buffer contain-
ing Tris-HCl 50mmoll
 1 (pH 9); KCL 50mmoll
 1; MgCl2
7mmoll
 1;( N H 4)2SO4 16mmoll
 1 (HT Biotechnologies, Cambridge,
UK): 0.5U SuperTaq poymerase (HT Biotechnologies); 25pmol
of each primer and 100ng of genomic DNA and sterile
water to make a uniform volume of 50ml. The reaction was
performed using an Omnigene thermal cycler (Hybaid, Tedding-
ton, UK). PCR products were analysed by single-stranded
conformational polymorphism (SSCP) on a multiphor II system
(Amersham Pharmacia Biotech) using an ExcelGel
s DNA Analysis
Kit (Amersham Pharmacia Biotech) and a Plus One t DNA silver
staining kit (Amersham Pharmacia Biotech) on a Hoefer
automated gel stainer. MSI was identified by the presence of a
characteristic ladder pattern in tumour DNA but not in the
corresponding normal mucosa. Cancers which demonstrated MSI
in 430% of the loci investigated were designated as MSI-H, those
with MSI in o30% of the loci were considered MSI-L and those
failing to demonstrate instability at any locus were classified as
MSS, in accordance with the guidelines laid down by the National
Cancer Institute workshop on MSI (Boland et al, 1998). Cancers
were categorised as MSI-H, while MSI-L and MSS were grouped
together.
Immunohistochemistry (IHC)
Formalin-fixed, paraffin-embedded cancer tissue sections 5mm
thick were mounted on superfrost slides (BDH Laboratory
Supplies) and held at 371C overnight. Paraffin was removed and
the tissue rehydrated using xylene and ethanol. Slides were
subjected to microwave antigen retrieval in 10mM citrate buffer
(pH 6) at 851C for 35min and cooled in phosphate-buffered saline
(PBS), pH 7.4 (Sigma). Endogenous peroxidase activity was
blocked with 2% hydrogen peroxide in methanol and slides were
washed with PBS prior to overnight incubation with the
appropriate antibody at a dilution of 1:100. Commercially
available monoclonal antibodies against the nuclear proteins
MLH1 (PharMingen International, Clone G168-15), MSH2
(Calbiochem-Novabiochem International, Clone FE11) and MSH6
(Serotec, Clone GTBP.P1/2.D4) were applied, followed by staining
with Strept ABC complex/HRP Duet kit (DAKO Ltd, Denmark) in
conjunction with diamino benzedene (DAB) 180mg in 300ml PBS
with 300mlH 2O2. Tissues were counterstained with Mayer’s
haematoxylin prior to mounting with DePex (BDH, Poole, UK).
Slide scoring was performed without prior knowledge of MSI
status. Loss of expression was determined by failure of the cancer
cell nuclei, but not the normal mucosa or stromal cells to stain.
Sections that did not stain or showed equivocal staining were
excluded from further analysis.
Methylation analysis
Methylation-specific PCR (MSP) following bisulfite modification
was performed on samples that failed to express the MLH1 gene
using published primer sequences (Herman et al, 1998) designed
to amplify either the methylated or unmethylated MLH1 promoter
region. For bisulphite modification, 5ml genomic DNA (100–
350ng of genomic DNA) was incubated for 10min at 371C with 1ml
of salmon sperm DNA and 1mlo f1 0N NaOH, and made up to 50ml
with deionised H2O. Freshly prepared 10mM hydroquinone (30ml)
(Sigma) and 3 M NaHSO3
  (520ml) (Sigma) were added, covered
with a layer of mineral oil and incubated at 501C for 18h. DNA
was cleaned using the QIAquick Gel Extraction Kit (Qiagen) in
accordance with the manufacturer’s instructions. The clean DNA
was incubated with 1.5ml1 0 M NaOH at room temperature for
10min (final concentration 0.3 M) prior to incubation at  301C
overnight with 1ml of glycogen (Ambion), 5mlo f3 M sodium
acetate and 125ml of 100% ethanol. DNA was subsequently washed
with 70% ethanol, air dried and re-suspended in sterile, deionised
H2O. Following MSP, the PCR products were analysed using 2%
agarose in Tris-borate-EDTA gel containing ethidium bromide at a
concentration of 0.05mg per 100ml (BDH-Merck) and visualised
under ultraviolet light.
Mutational analysis
Mutational analysis was performed on multiple cancer samples
with MSI-H that expressed the MLH1 and MSH2 proteins, as
demonstrated by immunohistochemistry. All 19 MLH1 and 16
MSH2 exons underwent PCR amplification using published primer
sequences (Kolodner et al, 1994; Wijnen et al, 1996) and were
analysed by SSCP and silver staining.
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The age at diagnosis of the cancers in the groups was compared by
Mann–Whitney U-test, while categorical data were compared by
Fisher’s exact test. All statistical analysis was performed using
GraphPad InStat version 3.00 for Windows 95, GraphPad Software,
San Diego, CA USA, www.graphpad.com.
RESULTS
The study group was representative of the Thames cancer registry
data. The age at diagnosis, (P¼0.11), gender (P¼0.4) and site
distribution (P¼0.22) of the study group were comparable to
those of the whole group in the Registry. There were proportion-
ally more patients with metachronous CRCs in the study group,
compared to the Registry (P¼0.012) (Table 1).
Microsatellite status
MSI-H was detected in 10 (13.5%). single cancers, MSI-L in 19
(25.5%) and MSS in 45 (61%) cancers. There was no difference
between the ages of patients with MSI-H (median 80, range 68–89
years) and with MSI-L/MSS (73.5, range 31–100 years) (P¼0.2).
There were more female patients with MSI-H (8 vs 2) than with
MSI-L/MSS (23 vs 41) (P¼0.01). MSI-H was detected in 58 (52%)
multiple cancers, a significantly higher incidence than in the single
cancers (Po0.001), MSI-L in 29 (26%) and MSS in 24 (22%)
multiple cancers. The ages of patients with MSI-H multiple cancers
(72.5, range 40–87 years) were similar to those in the MSI-L/MSS
group (median 73, range 35–91 years), P¼0.78. There was no
difference in the sex distribution in MSI-H (30 females vs 28 males)
and in MSI-L/MSS (30 females vs 23 males) cancers (P¼0.7).
In 46 patients with multiple cancers, only a single cancer was
available for analysis, 29 (63%) demonstrated MSI-H (median 71,
range 53–87 years) and 17 (37%) MSI-L/MSS (median 73 years,
range 53–87); the ages were not different in these groups (P¼0.9).
There was no difference in MSI-H in metachronous (35/62) or
synchronous (23/49) cancers (P¼0.3). In 32 patients, the MSI
status of two or more cancers obtained from a single patient was
available; in eight, MSI-H was detected in both cancers (one of
whom demonstrated MSI-H in three synchronous cancers); in 13
MSI-H was identified in a single cancer from a pair and MSI-L/
MSS in the corresponding cancer, and in 11 patients both cancers
demonstrated MSI-L/MSS. There was no difference between the
groups in the ages at diagnosis (Table 2).
Immunohistochemistry
Of the single cancers, 19 paraffin-embedded tissue samples were
inadequate for immunohistochemistry. Of nine MSI-H cancers,
six failed to express MLH1, one failed to express MSH2, and two
expressed MLH1 and MSH2. One of the MSI-L/MSS cancers failed
to express MSH2 and the remaining 45 expressed both MLH1 and
MSH2. All 55 cancers expressed MSH6 (Table 3). Of the multiple
cancers, 36 paraffin-embedded samples were inadequate for
immunohistochemistry. Of 43 MSI-H cancers, 14 failed to express
the MLH1, seven failed to express MSH2, while 22 expressed MLH1
and MSH2. Of 32 MSI-L/MSS cancers, 28 expressed MLH1 and
MSH2, three failed to express MLH1 and one failed to express
MSH2. Five MSI-H cancers failed to express the MSH6, of which
one failed to express MLH1, three failed to express MSH2 and only
one cancer failed to express MSH6 alone (Table 3).
There were 19 paired multiple cancers available for immuno-
histochemistry. In seven patients, both cancers demonstrated MSI-
H; three failed to express MSH2 and two failed to express MLH1 in
either cancer. One patient with three MSI-H synchronous cancers
showed normal MLH1, MSH2 and MSH6 expression in their













Right colon 56 694 0.4
Left colon 51 986
Sex
Male 34 367 0.22
Female 44 387
Metachronous 49 361 0.012
Synchronous 29 393







MSI-H in two or more cancers 8 73 (40–82) P¼0.15
MSI-H in one cancer 13 72.5 (56–84) P¼0.60
MSI-L/MSS in two or
more cancers
11 71 (35–82) P¼0.28
o
o
Table 3 Immunohistochemistry results for multiple and single cancers
MSI-H MSI-L/MSS
Negative staining Negative staining
Positive staining MLH1 MSH2 MSH6 Positive staining MLH1 MSH2 MSH6
Multiple cancers
Number 22 14 7 5 28 3 1 0
Median age (range) (years) 72.5 (40–84) years 73 (35–91) years
Single cancers
N u m b e r 2 610 4 5 010
Median age (range) (years) 80 (68–89) years 73.5 (38–100) years
)
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scancers, the last patient demonstrated loss of MLH1 in one
tumour, but MLH1, MSH2 and MSH6 expression in the other.
MSH6 expression was lost in two cancers that also failed to express
MSH2, the corresponding cancer pair also failed to express MSH2,
but expressed MSH6 (Table 4). In five patients, a single cancer
demonstrated MSI-H and the other showed MSI-L/MSS; one lost
MLH1 expression in both cancers, one showed loss of MLH1
expression in the MSI-H cancers but not in the MSI-L/MSS cancer,
while three patients expressed MLH1, MSH2 and MSH6 in both
cancers. In seven patients, both cancers demonstrated MSI-L/MSS,
a single cancer did not express MSH2, the remaining 13 cancers
expressed MLH1, MSH2 and MSH6.
In six patients, there was loss of expression of the same MMR
gene in paired cancers. Their ages at diagnosis (median 54.5, range
40–73 years) were lower than in those with a single MSI-H cancer
(median 75.5, range 60–84 years) (P¼0.003).
Methylation
Methylation analysis was carried out on all cancers that failed to
express the MLH1 gene protein. Of the single cancer group, three
of the six (50%) MSI-H cancers and 11 of 17 (65%) MSI-H multiple
cancers demonstrated promoter region methylation. Of three
patients with paired cancers that failed to express MLH1 in either
cancer, two failed to demonstrate methylation (patients no. 4 and
7) and the other (patient no. 5) showed promoter region
methylation in both cancers (Table 4).
Mutational analysis
In 10 MSI-H multiple cancers that expressed the MLH1 and MSH2
protein, no mutations were identified in either gene.
DISCUSSION
The incidence of MSI-H in multiple cancerss (52%) is significantly
higher than in single cancers (13.5%), consistent with other reports
(Sengupta et al, 1997; Brown et al, 1998; Masubuchi et al, 1999;
Pedroni et al, 1999; Yamashita et al, 2000). The presence of
patients with HNPCC, known to be associated with MSI-H in
490% of cancers, might account for this. Patients with multiple
CRCs due to HNPCC are expected to demonstrate concordant
MSI-H and loss of expression of the same mismatch repair gene in
all cancers. We identified concordant MSI-H in only 25% of paired
cancers, the remaining patients having either one or both MSI-L/
MSS cancers. Since the incidence of HNPCC in patients with MSI-
L/MSS cancers is very low (Terdiman et al, 2001), it is unlikely that
HNPCC is responsible for the development of multiple cancers
in 75% of patients. Of the 19 paired cancers from which tissue
was available for immunohistochemical analysis, five patients
Table 4 Immunohistochemistry and methylation data for ‘paired’ cancers
Patient number MSI status MSH2 expression MLH1 expression MSH6 expression MLH1 methylation Age at presentation
1H   |   —5 5
H   || —5 4
2H   |   —4 0
H   || —4 3
3H   || —5 3
H   || —4 2
4H |   |   50
H |   |   65
5H |   || 67
H |   || 73
6H ||| —7 6
H ||| —7 6
H ||| —7 6
7H |   |   62
L |   |   62
8H |   || 79
H |||   78
9H |   || 82
S |||   73
10 H ||| —7 5
L ||| —7 6
11 S ||| —8 4
H ||| —8 4
12 H ||| —6 0
L ||| —6 2
13 S   || —6 4
L ||| —6 7
14 L ||| —7 3
S ||| —7 3
15 L ||| —7 0
L ||| —7 2
16 S ||| —7 7
S ||| —7 8
17 L ||| —6 9
L ||| —7 3
18 S ||| —5 7
L ||| —5 9
19 L ||| —7 0
L ||| —7 3
|¼positive,  ¼negative, —¼not tested.
Role of MLH1, MSH2 and MSH6
DA Lawes et al
475




















sdemonstrated MSI-H with loss of a concordant MMR genes and
one demonstrated concordant loss of MLH1 expression in MSI-H
and MSI-L cancers, suggesting that 31% of patients might have
HNPCC. In addition, these patients were younger (median age 54.5
years) at the time of diagnosis than those with paired cancers in
which only one demonstrated MSI-H (75.5 years). Since the
median age of diagnosis of an HNPCC-related CRC is 42 years
(Aarnio et al, 1995), this supports our hypothesis. However, when
MLH1 promoter region methylation analysis was performed on
those MSI-H cancers that failed to express MLH1, one patient with
a paired MSI-H cancer demonstrated concordant methylation.
Since methylation accounts for loss of MLH1 function in up to
90% of sporadic CRC and is uncommon in HNPCC (Wheeler et al,
2000), it is more likely that this patient has developed two sporadic
cancers rather than having an underlying germline mutation,
suggesting that, on combined immunohistochemistry and MSI
analysis, only 26% of patients might have HNPCC. In addition, the
relatively high incidence of methylation in MLH1-negative cancers
(65%) throughout the group suggests that the majority of these
patients have a sporadic MSI-H cancer and that an underlying
germline mutation is not responsible.
Although the majority of the patients in our group do not
appear to have classical HNPCC, the role of alternative MMR
genes such as MSH6, PMS1, PMS2, MLH3 and EXO1 should be
considered (Akiyama et al, 1997; Miyaki et al, 1997; Thompson
et al, 2004). Since PMS1, MLH3 and EXO1 have only been
implicated in the development of colorectal cancers in case reports
(Liu et al, 1996;Hienonen et al, 2003;Thompson et al, 2004), they
are unlikely to be implicated in the development of cancer in our
group. However, MSH6 mutations may be involved in 5% of all
HNPCC families and give rise to atypical HNPCC with a delayed
onset of cancer. Although extra-colonic cancers, particularly
endometrial, appear to be more prevalent in this group (Plaschke
et al, 2004), MSH6 mutations have been implicated in the
development of 22% of Amsterdam criteria-positive criteria
patients with MSI-L cancers (Wu et al, 1999). Our finding that
MSH6 was expressed in all MSI-L and MSS cancers suggests that
it is unlikely to play a significant role in this group. Of the MSI-H
cancers, only five multiple cancers demonstrated loss of MSH6
expression, four of these also failed to express MSH2 or MLH1.I n
two cases, the paired cancer continued to express MSH6 normally,
while also failing to express MSH2, suggesting a secondary
mutation possibly in the intragenic C8 mononucleotide repeat
region of MSH6 as a result of loss of MLH1 or MSH2 function. In
only one case was MSH6 expression lost in isolation, rendering
a single patient a candidate for an underlying MSH6 germline
mutation. Mutational analysis in these cases may help clarify the
role of MSH6. Mutations of PMS2 have been shown to be
important in a small group of HNPCC patients (Thompson et al,
2004). Although primary mutations of PMS2 are uncommon, the
inclusion of PMS2 immunohistochemistry may aid the identifica-
tion of MLH1 germline mutations in MSI-H cancers that continue
to express MLH1 (Thompson et al, 2004). The addition of PMS2
immunohistochemistry may have improved the low concordance
between MSI-H and loss of MMR gene expression in multiple
cancers (49%). The sensitivity of immunohistochemical analysis in
our single cancers is in keeping with other series (Terdiman et al,
2001;Lindor et al, 2002), suggesting that this discrepancy is not due
to experimental error. Missense mutations or in-frame deletions
have been shown to account for the continued expression of a
nonfunctioning MMR protein (Peltomaki and Vasen, 1997;
Debniak et al, 2000; de Jong et al, 2004); therefore SSCP analysis
of all MLH1 and MSH2 exons in 10 patients was undertaken to
verify the immunohistochemistry result. Although intronic DNA
was not analysed and SSCP is only sensitive for 70% of mutations,
being particularly prone to miss large deletions (Grompe, 1993),
we feel that it is unlikely that mutations, if present, would not
have been identified in at least some of the 10 cancers studied.
PMS2 analysis may elucidate the underlying genetic cause in this
group.
In conclusion, although there is an increased incidence of
MSI-H in those who develop multiple colorectal cancers, the
majority are unlikely to be caused by HNPCC. In such cases, a
combination of MSI analysis and immunohistochemistry analysis
should be performed on both cancers to identify those who should
undergo more extensive genetic evaluation.
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